Skip to content

The Effect of Preoperative Oral Prednisone on the Operative Field During Nasal Polypectomy.

The Effect of Preoperative Oral Prednisone on the Operative Field During Nasal Polypectomy.

Status
Completed
Phases
Phase 3
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT00440219
Enrollment
34
Registered
2007-02-26
Start date
2010-11-30
Completion date
2013-06-30
Last updated
2014-01-10

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Nasal Polyps

Keywords

Nasal polyps, Steroids, Prednisone, Nasal polypectomy, Blood loss, surgical

Brief summary

This study aims to determine if a short course of oral prednisone helps to improve the operative field and ease of surgery by minimizing bleeding during nasal polypectomy surgery.

Detailed description

This study will be conducted as a double blinded randomized control trial and aims to recruit about 34 patients (17 patients per arm). Patients will be randomized to receive either prednisone 50 mg po x10 days or an identical looking placebo x10 days. Photographs of the polyps will be taken prior to the intervention, on the day of surgery and in the follow-up visit. Symptom survey (SNOT22) will also be administered at these same time points. Blood loss will be determined volumetrically from the suction canister and by using the Wormald Surgical field grading scale. Surgeons will also complete a survey postoperatively evaluating visibility, difficulty and ease of surgery. At 2 weeks, 1 month, 3 months and 6 months, patients will again fill out the Sino-nasal Outcome Test - 22 (SNOT-22) and the surgeon will do an endoscopic assessment by using the Peri-Operative Sinus Endoscopy (POSE) scoring system .

Interventions

Prednisone 50 mg once daily for 10 days pre-op

DRUGPlacebo comparator

Placebo pill identical to Prednisone 10 days once daily pre-op

Sponsors

Samuel Lunenfeld Research Institute, Mount Sinai Hospital
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
DOUBLE (Subject, Investigator)

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* All patients with severe obstructing nasal polyps scheduled for surgery.

Exclusion criteria

* Patient unable to tolerate side effects of prednisone * Uncontrolled diabetes mellitus * Hypertension * Previous congestive heart failure * Acute/chronic systemic infection * History of hypersensitivity to prednisone * History of cataracts or glaucoma

Design outcomes

Primary

MeasureTime frameDescription
Intraoperative blood loss. Wormald Surgical Field Grading ScaleIntraoperativeThis is an 11-point validated scale designed to provide a standardized method of documenting bleeding in endoscopic sinus surgery \[Athanasiadis et al., 2007\]. In addition blood loss during the surgery will be calculated from the suction canisters after accounting for the amount of irrigation used.
Visibility and easy of surgeryImmediate Postoperative periodThe surgeon will assess visibility and easy of surgery during the surgery and the technical difficulty of the surgery using two visual analogue scale questions.
Endoscopic assessment4 weeks, 3 months, 6 monthsThe Peri-Operative Sinus Endoscopy (POSE) scoring system (total score) will be used to assess the condition of the patients' sinus cavities and the Lindholdt scale will be used to provide objective measures of polyp recurrence size based on the percent obstruction of the nasal cavity and obstruction based on anatomic location.

Secondary

MeasureTime frameDescription
Quality of life survey (SNOT22)2 weeks, 4 weeks, 3 months, 6 months post-opThe Sino-nasal Outcome Test - 22 (SNOT-22) will be used as the main instrument to assess patients' disease specific symptoms. The total score from the SNOT-22 at 3 months follow-up will be the main outcome. The profile of symptom scores over the full follow-up period will be a secondary outcome.

Countries

Canada

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026